Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31084957 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL14933346 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29559656 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29518081 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| SCHEMBL29997203 | 1.00 | CALCRL (0.61) | CALCRLRAMP1 | |
| Hydrochloric Acid SCHEMBL31126002 | 0.99 | CALCRL (0.60) | CALCRLRAMP1 | |
| Water SCHEMBL29518115 | 0.99 | CALCRL (0.60) | CALCRLRAMP1 | |
| SCHEMBL4567288 | 0.90 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL4571727 | 0.87 | CALCRL (0.58) | CALCRLRAMP1 | |
| SCHEMBL31126005 | 0.87 | CALCRL (0.58) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737458-A2 | PROCESS FOR MAKING CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme LLC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3983416-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-12344621-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-07-01 | — | — | US | disclosed |
| US-20250136602-A1 | PROCESS FOR THE PREPARATION OF A PURE AMORPHOUS FORM OF UBROGEPANT | MSN LABORATORIES PRIVATE LIMITED, F&D CENTER (IN) | 2025-05-01 | — | — | US | disclosed |
| CN-114245798-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024150250-A1 | A PROCESS FOR THE PREPARATION OF ATOGEPANT AND ITS INTERMEDIATES | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024150250-A1 | A PROCESS FOR THE PREPARATION OF ATOGEPANT AND ITS INTERMEDIATES | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024134683-A1 | Novel process for the preparation of intermediate compounds used in the treatment of migraine | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024134683-A1 | Novel process for the preparation of intermediate compounds used in the treatment of migraine | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2024-06-27 | — | — | WO | disclosed |
| EP-4357020-A2 | ASYMMETRIC PHASE TRANSFER CATALYSIS | Merck Sharp & Dohme LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2012064910-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136602-A1 | PROCESS FOR THE PREPARATION OF A PURE AMORPHOUS FORM OF UBROGEPANT | UBA1, UGT1A1, UBA3 | CALCRL 3334/4885RAMP1 2005/4885 |
| US-20120122900-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
| US-12344621-B2 | CGRP antagonist compounds | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 63/4885 |
| US-20120122899-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | CALCRL 1/4885RAMP1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.